CliffBio
small molecule

CARGLUMIC ACID

CARGLUMIC ACID

Loss of exclusivity—loss of exclusivity
CompanyNovitium Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameCARGLUMIC ACID
Active ingredientCARGLUMIC ACID
Strength200MG
Dosage formTABLET, FOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2021
Marketing statusRX

More from Novitium Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.